In his letter suggesting alternative titles to my outcome study,1 Dr. Tebbetts assumes that because the majority of interviews were conducted less than 6 months after surgery, most of the patients were lost to follow-up within 6 months as well. In fact, many patients returned for appointments after their interviews. The mean follow-up time for surveyed patients who were also included in a prospective 10-year clinical study2 was 9 months. Of course, Dr. Tebbetts was unaware of this subsequent clinical publication when he wrote his letter. In response to his question as to whether outcomes are definable at 6 months or less, the answer is yes.3 Unlike liposuction or rhinoplasty, breast augmentation patients do not need to wait long to appreciate the impact of their operation. This time frame is also ideal to assess the patient’s recollection of her recovery experience. It is inadequate for long-term assessment of complications and reoperations, as noted in both articles.1,2 Insistence on longer follow-up times would reduce the inclusion rate, jeopardizing reliability. This is not to say that follow-up time is not an important consideration. On the contrary, the issue was taken seriously enough to investigate with two statistical analyses. Reassuringly, survey responses were found to be unrelated to follow-up times.1
Preoperative tissue measurements have not been shown to be effective. They tend to underestimate implant volumes. In a study of implants with a mean volume of 289 cc, Adams reports that approximately 20 percent of his patients express concerns to his staff regarding postoperative breast size.4 There are problems with basing volumes on tissue measurements. The base width is considered a critical dimension5 but is overlooked if the breast is too narrow. The inframammary fold serves as a “fixed landmark”5; however, it is known to drop after breast augmentation,6 whether by intention or not. Measuring the soft-tissue thickness does not affect management if one consistently uses the submuscular plane. The skin’s ability to stretch, even in nulliparous women, is well known and is usually not a limiting factor for volumes less than approximately 450 cc. Ptosis is relevant to whether a simultaneous mastopexy is recommended, not implant size. An implant should not be expected to take up the slack.7
Most plastic surgeons, even those performing tissue measurements, ultimately base their volume determinations on their judgment and experience, prioritizing their patients’ objectives. This clinical process is the basis of all cosmetic surgery. It is not “random” and it is certainly less rigid than relying on arbitrary numbers on a measurement form. Dr. Tebbetts suggests that I have a personal preference for “large” (mean volume, 390 cc) implants. In fact, a wide range of sizes is recommended (Fig. 1).1 A similar size distribution and a 385-cc average implant volume were recently reported by other investigators.8
Tebbetts does not offer data to support his repeated warnings that implants larger than 350 cc create excessive long-term tissue-related problems.9 No increased risk of complications in patients with larger implants was found in my 10-year clinical study that included 522 consecutive cases of breast augmentation and 146 consecutive cases of augmentation/mastopexy.2 On the contrary, a significant positive correlation was detected between larger implant size and a higher result rating.1 Clinical decisions rest on the risk-to-benefit ratio. Even if there were an increased risk, women who desire larger breast sizes may be willing to trade more risk for more benefit. Surgeon size prejudices should not keep them from achieving their goals; it is their choice after all.
Complication and reoperation rates are reported separately,2 including the requested reference on the limitations of reoperation rates.10 Dr. Tebbetts believes that having zero reoperations11 is a marker of surgical prowess. This may be true for a cholecystectomy, where a low reoperation rate may reflect, for example, the surgeon’s care not to injure the common bile duct. In cosmetic surgery, the criterion for success is much more subjective and patient-oriented. Unlike general surgery, patient perception of the cosmetic result is the most important indicator of surgical success.12 Reoperation rates are an unreliable marker of quality in cosmetic surgery.10 A reported rate of zero complications and zero reoperations11 is unique. Other experienced plastic surgeons report reoperation rates between 10.7 and 19.4 percent.2,8,13
Is a 5-year prospective outcomes study just a “snapshot”? By comparison, Dr. Tebbetts’ staff telephoned his patients for 3 days after submuscular breast augmentations and concluded that 96 percent of his patients were fully recovered at 24 hours, to the extent that they were not taking prescription painkillers, were driving, could return to work, and were able to lie prone on their breasts for 15 minutes.14 Such findings stand in stark contrast to patient-reported outcomes data.1
Dr. Tebbetts’ regimented surgical philosophy includes personal preferences (e.g., not touching the perichondrium, cautery dissection only, “<1-cc blood loss,” general endotracheal anesthesia with muscle paralysis) that are intended to eliminate or minimize the postoperative recovery period.14 However, these practice recommendations are not well supported by clinical or physiologic evidence. Blunt dissection reduces burn injury and is safer for sensory nerve branches. Greater efficiency is welcome—it reduces anesthesia time and recovery room stays, and improves profitability—but it is difficult to believe that reducing surgery times to only 24 minutes truly expedites the patient’s return to normal activity by 80 percent.14 Even if it did, few patients would want their surgeon to be racing against the clock.
Fortunately, as this outcomes study demonstrates, patient satisfaction remains high, provided that complications are recognized and treated appropriately.1 There will always be a need for size changes. After all, women’s opinions are known to change after surgery. Breast implants, surgery, surgeons, and patients are all imperfect. Reoperating when indicated is better than defending an unsatisfactory result, and is part of postoperative care. By listening to our patients carefully, we may better meet their expectations.
The author has no conflicts of interest to disclose. There was no outside funding for this study.
Eric Swanson, M.D.
11413 Ash Street
Leawood, Kans. 66211
1. Swanson E. Prospective outcome study of 225 cases of breast augmentation. Plast Reconstr Surg. 2013;131:1158–1166; discussion 1167–1168.
2. Swanson E. Prospective comparative clinical evaluation of 784 consecutive cases of breast augmentation and vertical mammaplasty, performed individually and in combination. Plast Reconstr Surg. 2013;132:30e–45e.
3. McCarthy CM, Cano SJ, Klassen AF, et al. The magnitude of effect of cosmetic breast augmentation on patient satisfaction and health-related quality of life. Plast Reconstr Surg. 2012;130:218–223.
4. Adams WP Jr. The process of breast augmentation: Four sequential steps for optimizing outcomes for patients. Plast Reconstr Surg. 2008;122:1892–1900.
5. Tebbetts JB, Adams WP. Five critical decisions in breast augmentation using five measurements in 5 minutes: The high five decision support process. Plast Reconstr Surg. 2005;116:2005–2016.
6. Swanson E. Photometric evaluation of inframammary crease level after cosmetic breast surgery. Aesthet Surg J. 2010;30:832–837.
7. Swanson E. Prospective photographic measurement study of 196 cases of breast augmentation, mastopexy, augmentation/mastopexy, and breast reduction. Plast Reconstr Surg. 2013;131:802e–819e.
8. Lista F, Tutino R, Khan A, Ahmad J. Subglandular breast augmentation with textured, anatomic, cohesive silicone implants: A review of 440 consecutive patients. Plast Reconstr Surg. 2013;132:295–303.
9. Tebbetts JB. The greatest myths in breast augmentation. Plast Reconstr Surg. 2001;107:1895–1903.
10. Pollock H, Pollock T. Is reoperation rate a valid statistic in cosmetic surgery? Plast Reconstr Surg. 2007;120:569
11. Tebbetts JB. Achieving a zero percent reoperation rate at 3 years in a 50-consecutive-case augmentation mammaplasty premarket approval study. Plast Reconstr Surg. 2006;118:1453–1457.
12. Pusic AL, Klassen AF, Scott AM, Klok JA, Cordeiro PG, Cano SJ. Development of a new patient-reported outcome measure for breast surgery: The BREAST-Q. Plast Reconstr Surg. 2009;124:345–353.
13. Maxwell GP, Van Natta BW, Murphy DK, Slicton A, Bengtson BP. Natrelle style 410 form-stable silicone breast implants: Core study results at 6 years. Aesthet Surg J. 2012;32:709–717.
14. Tebbetts JB. Achieving a predictable 24-hour return to normal activities after breast augmentation: Part I. Refining practices by using motion and time study principles. Plast Reconstr Surg. 2002;109:273–290; discussion 291.
Letters to the Editor, discussing material recently published in the Journal, are welcome. They will have the best chance of acceptance if they are received within 8 weeks of an article’s publication. Letters to the Editor may be published with a response from the authors of the article being discussed. Discussions beyond the initial letter and response will not be published. Letters submitted pertaining to published Discussions of articles will not be printed. Letters to the Editor are not usually peer reviewed, but the Journal may invite replies from the authors of the original publication. All Letters are published at the discretion of the Editor.
Letters submitted should pose a specific question that clarifies a point that either was not made in the article or was unclear, and therefore a response from the corresponding author of the article is requested.
Authors will be listed in the order in which they appear in the submission. Letters should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/.
We reserve the right to edit Letters to meet requirements of space and format. Any financial interests relevant to the content of the correspondence must be disclosed. Submission of a Letter constitutes permission for the American Society of Plastic Surgeons and its licensees and asignees to publish it in the Journal and in any other form or medium.
The views, opinions, and conclusions expressed in the Letters to the Editor represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.
The Journal requests that individuals submit no more than five (5) letters to Plastic and Reconstructive Surgery in a calendar year.